The Ohio State University Dermatology Biorepository
Part of paid clinical trials in Columbus, Ohio.
- Sponsor
- Ohio State University
- Study ID
- NCT03146676
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - N/A
- Healthy Volunteers
- Accepted
Study Details
This study will create and extend a source of clinical specimens for the future study of inflammatory skin disorders.
Key Dates
- First listed
- May 10, 2017
- Start date
- Apr 19, 2017
- Status verified
- Feb 2026
- Primary completion
- Dec 31, 2030
- Completion
- Dec 31, 2030
Study Design
- Enrollment
- 175 participants (estimated)
Primary Outcome Measure
Source of clinical specimens for the future study of neoplastic and inflammatory skin disorders [ Time Frame: 5 years ]
Central Contacts
- Alison Rocchi614-685-0251
- Kristina Susi614-814-1277
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| OSU Dermatology West | Columbus | Ohio | 43215 | Benjamin Kaffenberger, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Columbus, OH
Nationwide
By condition
By specialty
By research site
Related Studies
- Myriad™ Augmented Soft Tissue Reconstruction RegistryRecruiting · Aroa Biosurgery Limited · Phoenix, Arizona
- A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis SuppurativaPHASE3 · Enrolling By Invitation · MoonLake Immunotherapeutics AG · Birmingham, Alabama
- Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis SuppurativaPHASE1 · Recruiting · Incyte Corporation · Phoenix, Arizona
- A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.PHASE2 · Recruiting · Pfizer · Phoenix, Arizona